{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-075678","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.996497+00:00","generated_at":"2026-05-17T13:58:21.416827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jasper Therapeutics Q2 net loss $26.7M; cuts workforce 50%, probes BEACON lot issue","bullets":["Net loss of $26.7M ($1.74 per share); cash and equivalents $39.5M as of June 30, 2025.","BEACON study: 89% complete response in 240/360 mg single-dose cohorts; investigation into 240mg Q8W/240/180mg Q8W cohorts due to potential product lot variability.","Workforce reduction of ~50% to focus on urticaria; CMO Dr. Edwin Tucker stepped down, succeeded by Dr. Daniel Adelman as interim.","Halted non-mast cell programs (SCID, asthma ETESIAN study) to concentrate on briquilimab in CSU and CIndU."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-075678","json":"https://secwatch.observer/filing/0001213900-25-075678.json","markdown":"https://secwatch.observer/filing/0001213900-25-075678.md","text":"https://secwatch.observer/filing/0001213900-25-075678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/0001213900-25-075678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea0252991-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:21.416827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}